Cantargia AB (publ) (STO: CANTA)

Market Cap	339.64M
Revenue (ttm)	n/a
Net Income (ttm)	-193.53M
Shares Out	183.69M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	374,284
Open	1.830
Previous Close	1.833
Day's Range	1.811 - 1.847
52-Week Range	1.767 - 5.200
Beta	1.72
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 21, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA